Challenging conventional wisdom: The etiologic role of dopamine oxidative stress in Parkinson's disease

Movement Disorders

Volumn 20, Issue 3, 2005, Pages 271-282

  Ahlskog, J Eric ^a  

^a MAYO CLINIC   (United States)

Author keywords

Dopamine; Levodopa; Oxidative stress; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE; NEUROMELANIN; OXYGEN RADICAL; PLACEBO; PROTEASOME; REACTIVE OXYGEN METABOLITE; UBIQUITIN;

AEROBIC METABOLISM; BRAIN NERVE CELL; CELL DESTRUCTION; CONSTIPATION; DEGENERATIVE DISEASE; DEMENTIA; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; HUMAN; HYPOTHESIS; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; OXIDATIVE STRESS; PARKINSON DISEASE; PREDICTION; PRIORITY JOURNAL; REM SLEEP; REVIEW; SLEEP DISORDER; SMELLING DISORDER; SYMPTOMATOLOGY;

BRAIN STEM; DEMENTIA; DOPAMINE; HUMANS; LEWY BODIES; NERVE DEGENERATION; NERVE TISSUE PROTEINS; OLFACTION DISORDERS; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; REM SLEEP BEHAVIOR DISORDER; SYNUCLEINS; UBIQUITIN;

EID: 18144412688     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20362     Document Type: Review

References (192)

1. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 1989;52:1830-1836.
2. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MB. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 1991;56:978-982.
3. Dexter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994;35:38-44.
4. Ambani LM, Van-Woert MH, Murphy S. Brain peroxidase and catalase in Parkinson's disease. Arch Neurol 1975;32:114-118.
5. Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 1982;33:305-310.
6. Kish SJ, Mortio C, Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett 1985;58:343-346.
7. Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 1992;142:128-130.
8. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994;36:348-355.
9. Hirsch E, Graybiel AM, Agid Y. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988;334:345-348.
10. Spina MB, Cohen G. Dopamine turnover and glutathione oxidation: implications for Parkinson disease. Proc Natl Acad Sci U S A 1989;86:1398-1400.
11. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40(Suppl. 3):32-37.
12. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992;32:804-812.
13. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989;52:381-389.
14. Dexter DT, Holley AE, Flitter WD, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord 1994;9:92-97.
15. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A 1996;93:2696-2701.
16. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 1997;69:1326-1329.
17. Zhang J, Perry G, Smith MA, et al. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 1999;154:1423-1429.
18. Alam ZI, Jenner A, Daniel SE, et al. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 1997;69: 1196-1203.
19. Good PF, Hsu A, Werner P, Perl DP, Olanow CW. Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 1998; 57:338-342.
20. Duda JE, Giasson BI, Chen Q, et al. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol 2000;157:1439-1445.
21. Giasson BI, Duda JE, Murray IV, et al. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science 2000;290:985-989.
22. McNaught KS, Olanow CW. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann Neurol 2003;53(Suppl. 3):S73-S84.
23. Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 2000;20:6048-6054.
24. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001;294:1346-1349.
25. Xu J, Kao SY, Lee FJ, Song W, Jin LW, Yankner BA. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002; 8:600-606.
26. Lotharius J, Brundin P. Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum Mol Genet 2002;11:2395-2407.
27. Butterfield DA, Castegna A, Lauderback CM, Drake J. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol Aging 2002;23:655-664.
28. Albers DS, Augood SJ. New insights into progressive supranuclear palsy. Trends Neurosci 2001;24:347-353.
29. Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington's disease. Brain Pathol 1999;9:147-163.
30. Minghetti L, Greco A, Cardone F, et al. Increased brain synthesis of prostaglandin E2 and F2-isoprostane in human and experimental transmissible spongiform encephalopathies. J Neuropathol Exp Neurol 2000;59:866-871.
31. Cookson MR, Shaw PJ. Oxidative stress and motor neurone disease. Brain Pathol 1999;9:165-186.
32. Vladimirova O, O'Connor J, Cahill A, Alder H, Butunoi C, Kalman B. Oxidative damage to DNA in plaques of MS brains. Multiple Sclerosis 1998;4:413-418.
33. Milatovic D, Zhang Y, Olson SJ, et al. Herpes simplex virus type 1 encephalitis is associated with elevated levels of F2-isoprostanes and F4-neuroprostanes. J Neurovirol 2002;8:295-305.
34. Maritim AC, Sanders RA, Watkins JB III. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003; 17:24-38.
35. Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-272.
36. Nakano I, Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 1984;15:415-418.
37. Jellinger K. Overview of morphological changes in Parkinson's disease. Adv Neurol 1987;45:1-18.
38. Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson's disease and in progressive supranuclear palsy. Proc Natl Acad Sci U S A 1987;84:5976-5980.
39. Zweig RM, Jankel WR, Hedreen JC, Mayeux R, Price DL. The pedunculopontine nucleus in Parkinson's disease. Ann Neurol 1989;26:41-46.
40. Halliday GM, Li YW, Blumbergs PC, et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 1990;27:373-385.
41. Gai WP, Halliday GM, Blumbergs PC, Geffen LB, Blessing WW. Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson's disease. Brain 1991;114: 2253-2267.
42. Jellinger KA. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 1991;14: 153-197.
43. Eadie MJ. The pathology of certain medullary nuclei in parkinsonism. Brain 1963;86:781-792.
44. Gai WP, Blumbergs PC, Geffen LB, Blessing WW. Age-related loss of dorsal vagal neurons in Parkinson's disease. Neurology 1992;42:2106-2111.
45. Del Tredici K, Rub U, De Vos RA, Bohl JR, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002;61:413-426.
46. Halliday GM, Blumbergs PC, Cotton RGH, Howe PRC, Blessing WW, Geffen LB. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease. Brain Res 1990;510: 104-107.
47. Malessa S, Hirsch EC, Cervera P, Duyckaerts C, Agid Y. Catecholaminergic systems in the medulla oblongata in parkinsonian syndromes: a quantitative immunohistochemical study in Parkinson's disease, progressive supranuclear palsy, and striatonigral degeneration. Neurology 1990;40:1739-1743.
48. Saper CB, Sorrentino DM, German DC, de Lacalle S. Medullary catecholaminergic neurons in the normal human brain and Parkinson's disease. Ann Neurol 1991;29:577-584.
49. Braak H, Rub U, Sandmann-Keil D, et al. Parkinson's disease: affection of brain stem nuclei controlling premotor and motor neurons of the somatomotor system. Acta Neuropathol (Berl) 2000;99:489-495.
50. Braak E, Sandmann-Keil D, Rub U, et al. Alpha-synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei. Acta Neuropathol (Berl) 2001;101:195-201.
51. Langston JW, Forno LS. The hypothalamus in Parkinson's disease. Ann Neurol 1978;3:129-133.
52. Matzuk MM, Saper CB. Preservation of hypothalamic dopaminergic neurons in Parkinson's disease. Ann Neurol 1985;18:552-555.
53. Purba JS, Hofman MA, Swaab DF. Decreased number of oxytocin-immunoreactive neurons in the paraventricular nucleus of the hypothalamus in Parkinson's disease. Neurology 1994;44:84-89.
54. Braak H, Braak E, Yilmazer D, Schultz C, de Vos RA, Jansen EN. Nigral and extranigral pathology in Parkinson's disease. J Neural Transm Suppl 1995;46:15-31.
55. Pearson J, Goldstein M, Kitahama K, Sakamoto N, Michel JP. Catecholaminergic neurons of the human central nervous system. In: Riederer P, Kopp N, Pearson J, editors. An introduction to neurotransmission in health and disease. New York: Oxford University Press; 1990. p 22-36.
56. Rub U, Del Tredici K, Schultz C, et al. Parkinson's disease: the thalamic components of the limbic loop are severely impaired by alpha-synuclein immunopositive inclusion body pathology. Neurobiol Aging 2002;23:245-254.
57. Henderson JM, Carpenter K, Cartwright H, Halliday GM. Degeneration of the centre median-parafascicular complex in Parkinson's disease. Ann Neurol 2000;47:345-352.
58. Braak H, Braak E, Yilmazer D, et al. Amygdala pathology in Parkinson's disease. Acta Neuropathol (Berl) 1994;88;493-500.
59. Harding AJ, Stimson E, Henderson JM, Halliday GM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 2002;125:2431-2445.
60. Pearce RKB, Hawkes CH, Daniel SE. The anterior olfactory nucleus in Parkinson's disease. Mov Disord 1995;10:283-287.
61. Ikemoto K, Nagatsu I, Kitahama K, et al. A dopamine-synthesizing cell group demonstrated in the human basal forebrain by dual labeling immunohistochemical technique of tyrosine hydroxylase and aromatic L-amino acid decarboxylase. Neurosci Lett 1998; 243:129-132.
62. Hoogland PV, Huisman E. Tyrosine hydroxylase immunoreactive structures in the aged human olfactory bulb and olfactory peduncle. J Chem Neuroanat 1999;17:153-161.
63. Huisman E, Uylings HBM, Hoogland PV. A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease. Mov Disord 2004;19:571-579.
64. Wakabayashi K, Takahashi H. The intermediolateral, nucleus and Clarke's column in Parkinson's disease. Acta Neuropathol (Berl) 1997;94:287-289.
65. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 1997; 38(Suppl. 2):2-7.
66. Wakabayashi K, Takahashi H, Ohama E, Ikuta F. Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol (Berl) 1990;79:581-583.
67. Iwanaga K, Wakabayashi K, Yoshimoto M, et al. Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases. Neurology 1999;52:1269-1271.
68. Gotz ME, Freyberger A, Riederer P. Oxidative stress: a role in the pathogenesis of Parkinson's disease. J Neural Transm Suppl 1990;29:241-249.
69. Gibb WRG, Fearnley JM, Lees AJ. The anatomy and pigmentation of the human substantia nigra in relation to selective neuronal vulnerability. In: Streifler MB, Korczyn AD, Melamed E, Youdim MB, editors. Parkinson's disease: anatomy, pathology and therapy. New York: Raven Press; 1990. p 31-34.
70. Gibb WRG. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res 1992;581:283-291.
71. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
72. McRitchie DA, Cartwright HR, Halliday GM. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. Exp Neurol 1997;144:202-213.
73. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999;122:1421-1436.
74. Mouatt-Prigent A, Agid Y, Hirsch EC. Does the calcium binding protein calretinin protect dopaminergic neurons against degeneration in Parkinson's disease? Brain Res 1994;668:62-70.
75. Porritt MJ, Batchelor PE, Hughes AJ, Kalnins R, Donnan GA, Howells DW. New dopaminergic neurons in Parkinson's disease striatum. Lancet 2000;356:44-45.
76. Forno LS. Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism. J Am Geriatr Soc 1969;17:557-575.
77. Gibb WR. Idiopathic Parkinson's disease and the Lewy body disorders. Neuropathol Appl Neurobiol 1986;12:223-234.
78. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
79. Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (pre-clinical and clinical stages). J Neurol 2002;249(Suppl. 3):III/1-III/5.
80. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
81. Jellinger KA. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution - a pilot study. Acta Neuropathol (Berl) 2003;106:191-201.
82. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol (Berl) 1988;76:217-221.
83. Morrish PK, Sawle GV, Brooks DJ. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996;119:585-591.
84. Morrish PK, Sawle GV, Brooks DJ. The rate of progression of Parkinson's disease. A longitudinal [18F]DOPA PET study. Adv Neurol 1996;69:427-431.
85. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with (18F)dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.
86. Brooks DJ. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J Neurol 2000; 247(Suppl. 2):II/11-II/18.
87. Byrne KG, Pfeiffer R, Quigley EM. Gastrointestinal dysfunction in Parkinson's disease. A report of clinical experience at a single center. J Clin Gastroenterol 1994;19:11-16.
88. Korczyn AD. Autonomic nervous system screening in patients with early Parkinson's disease. In. Przuntek H, Riederer P, editors. Early diagnosis and preventive therapy in Parkinson's disease. Vienna: Springer-Verlag; 1989. p 41-48.
89. Ashraf W, Pfeiffer RF, Park F, Lof J, Quigley EM. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov Disord 1997;12:946-951.
90. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001;57:456-462.
91. Singaram C, Ashraf W, Gaumnitz EA, et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995;346:861-864.
92. Mathers SE, Kempster PA, Swash M, Lees AJ. Constipation and paradoxical puborectalis contraction in anismus and Parkinson's disease: a dystonic phenomenon? J Neurol Neurosurg Psychiatry 1988;51:1503-1507.
93. Edwards LL, Quigley EMM, Harned RK, Hofman R, Pfeiffer R. Defecatory function in Parkinson's disease: response to apomorphine. Ann Neurol 1993;33:490-493.
94. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol 1993;34:710-714.
95. Comella CL, Nardine TM, Diederich NJ, Stebbins GT. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology 1998;51:526-529.
96. Olson EJ, Boeve BF, Silber MH. Rapid eye movement sleep behavior disorder: demographic, clinical and laboratory findings in 93 cases. Brain 2000;123:331-339.
97. Eisensehr I, v Lindeiner H, Jager M, Noachtar S. REM sleep behavior disorder in sleep-disordered patients with versus without Parkinson's disease: is there need for polysomnography? J Neurol Sci 2001;186:7-11.
98. Gagnon J-F, Bedard M-A, Fantini ML, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002;59:585-589.
99. Albin RLM, Koeppe RAP, Chervin RDM, et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 2000;55:1410-1412.
100. Eisensehr I, Linke R, Noachtar S, Schwarz J, Gildehaus FJ, Tatsch K. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison with Parkinson's disease and controls. Brain 2000;123:1155-1160.
101. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology 1996;46:388-393.
102. Uchiyama M, Isse K, Tanaka K, et al. Incidental Lewy body disease in a patient with REM sleep behavior disorder. Neurology 1995;45:709-712.
103. Sastre JP, Sakai K, Jouvet M. Bilateral lesions of the dorso-lateral pontine tegmentum II - effect upon muscle atonia. Sleep Res 1978;7:44.
104. Hendricks JC, Morrison AR, Mann GL. Different behaviors during paradoxical sleep without atonia depend on pontine lesion site. Brain Res 1982;239:81-105.
105. Culebras A, Moore JT. Magnetic resonance findings in REM sleep behavior disorder. Neurology 1989;39:1519-1523.
106. Kimura K, Tachibana N, Kohyama J, Otsuka Y, Fukazawa S, Waki R. A discrete pontine ischemic lesion could cause REM sleep behavior disorder. Neurology 2002;55:894-895.
107. Braak H, Braak E. Pathoanatomy of Parkinson's disease. J Neurol 2000;247(Suppl. 2):II3-II10.
108. Jacobs BL. Single unit activity of locus coeruleus neurons in behaving animals. Prog Neurobiol 1986;27:183-194.
109. Singh S, Mallick BN. Mild electrical stimulation of pontine tegmentum around locus coeruleus reduces rapid eye movement sleep in rats. Neurosci Res 1996;24:227-235.
110. Gagnon J, Bedard M, Fantini ML, et al. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002;59:585-589.
111. Tan A, Salgado M, Fahn S. Rapid eye movement sleep behavior disorder preceding Parkinson's disease with therapeutic response to levodopa. Mov Disord 1996;11:214-216.
112. Fantini MLMDM, Gagnon JFM, Filipini DM, Montplaisir JMDP. The effects of pramipexole in REM sleep behavior disorder. Neurology 2003;61:1418-1420.
113. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988;38:1237-1244.
114. Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI. Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1992; 55:138-142.
115. Hawkes C. Olfaction in neurodegenerative disorder. Mov Disord 2003;18:364-372.
116. Montgomery EB Jr, Baker KB, Lyons K, Koller WC. Abnormal performance on the PD test battery by asymptomatic first-degree relatives. Neurology 1999;52:757-762.
117. Berendse HW, Booij J, Francot CMJE, et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 2001;50:34-41.
118. Roth J, Radil T, Ruzicka E, Jech R, Tichy J. Apomorphine does not influence olfactory thresholds in Parkinson's disease. Funct Neurol 1998;13:99-103.
119. Doty RL, Singh A, Tetrud J, Langston JW. Lack of major olfactory dysfunction in MPTP-induced parkinsonism. Ann Neurol 1992;32:97-100.
120. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
121. de la Fuente-Fernandez R, Lu J-Q, Sossi V, et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001;49:298-303.
122. Bonnet A-M, Loria Y, Saint-Hilaire M-H, Lhermitte F, Agid Y. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology 1987;37:1539-1542.
123. Agid Y, Graybiel AM, Ruberg M, et al. The efficacy of levodopa treatment declines in the course of Parkinson's disease: do non-dopaminergic lesions play a role? In: Streifler MB, Korczyn AD, Melamed E, Youdim MB, editors. Parkinson's disease: anatomy, pathology, and therapy. New York: Raven Press; 1990. p 83-100.
124. Apaydin H, Ahlskog JE, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Arch Neurol 2002;59:102-112.
125. Bugiani O, Perdelli F, Salvarani S, Leonardi A, Mancardi GL. Loss of striatal neurons in Parkinson's disease: a cytometric study. Eur Neurol 1980;19:339-344.
126. Bockelmann R, Wolf G, Ransmayr G, Riederer P. NADPH-diaphorase/nitric oxide synthase containing neurons in normal and Parkinson's disease putamen. J Neural Transm Park Dis Dement Sect 1994;7:115-121.
127. Lach B, Grimes D, Benoit B, Minkiewicz-Janda A. Caudate nucleus pathology in Parkinson's disease: ultrastructural and biochemical findings in biopsy material. Acta Neuropathol (Berl) 1992;83:352-360.
128. McNeill TH, Brown SA, Rafols JA, Shoulson I. Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease. Brain Res 1988;455:148-152.
129. Ahlskog JE, Richelson E, Nelson A, et al. Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients. Ann Neurol 1991; 30:185-191.
130. Shoji M, Harigaya Y, Sasaki A, et al. Accumulation of NACP/alpha-synuclein in Lewy body disease and multiple system atrophy. J Neurol Neurosurg Psychiatry 2000;68:605-608.
131. Duda JE, Giasson BI, Mabon ME, Lee VM, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 2002;52:205-210.
132. Irizarry MC, Growdon W, Gomez-Isla T, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol 1998;57:334-337.
133. MacDonald V, Halliday GM. Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease. Mov Disord 2002;17:1166-1173.
134. Mayeux R, Chen J, Mirabello E, et al. An estimate of the incidence of dementia in idiopathic Parkinson's disease. Neurology 1990;40:1513-1517.
135. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916-1921.
136. Mattila PM, Rinne JO, Helenius H, Dickson DW, Royatta M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol (Berl) 2000;100:285-290.
137. Kovari E, Gold G, Herrmann FR, et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol (Berl) 2003;106:83-88.
138. Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004;127:791-800.
139. Sweet RD, Mc Dowell FH. Five years' treatment of Parkinson's disease with levodopa: therapeutic results and survival of 100 patients. Ann Intern Med 1975;83:456-463.
140. Diamond SG, Markham CH. Present mortality in Parkinson's disease: the ratio of observed to expected deaths with a method to calculate expected deaths. J Neural Transm 1976;38:259-269.
141. Zumstein H, Siegfried J. Mortality among Parkinson patients treated with L-dopa combined with a decarboxylase inhibitor. Eur Neurol 1976;14:321-327.
142. Martilla RJ, Rinne UK, Siirtola T, Sonninen V. Mortality of patients with Parkinson's disease treated with levodopa. J Neurol 1977;216:147-118.
143. Joseph C, Chassan JB, Koch ML. Levodopa in Parkinson's disease: a long-term appraisal of mortality. Ann Neurol 1978;3:116-118.
144. Hoehn MMM. Parkinson's disease: progression and mortality. Adv Neurol 1986;45:457-461.
145. Uitti RJ, Ahlskog JE, Maraganore DM, et al. Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project. Neurology 1993;43:1918-1926.
146. Parkinson-Study-Group. Does levodopa slow or hasten the rate of progression of Parkinson Disease? The results of the Elldopa trial. Neurology 2003;60(Suppl. 1):A80.
147. Olanow CW, Hauser R, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
148. Markham CH, Diamond SG. Long-term follow-up of early dopa treatment in Parkinson's disease. Ann Neurol 1986;19:365-372.
149. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987;22:8-12.
150. Parkinson-Study-Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
151. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54:93-101.
152. Ahlskog JE. Slowing Parkinson's disease progression. Recent dopamine agonist trials. Neurology 2003;60:381-389.
153. Albin RL, Frey KA. Initial agonist treatment of Parkinson's disease. A critique. Neurology 2003;60:390-394.
154. Yahr MD, Wolf A, Antunes J-L, Miyoshi K, Duffy P. Autopsy findings in parkinsonism following treatment with levodopa. Neurology 1972;22(Suppl.):56-71.
155. Quinn N, Parkes D, Janota I, Marsden CD. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1986;1:65-68.
156. Rajput AH, Fenton ME, Dhand A. Is levodopa toxic to nonde-generating substantia nigra cells? Clinical evidence. Neurology 1996;46(Suppl.):A371.
157. Cotzias GC, Miller ST, Tang LC, Papavasiliou PS, Wang YY. Levodopa, fertility and longevity. Science 1977;196:549-551.
158. Sahakian BJ, Carlson KR, De Girolami U, et al. Functional and structural consequences of long-term dietary L-dopa treatment in mice. Commun Psychopharmacol 1980;4:169-176.
159. Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998;43:561-575.
160. Fornai F, Battaglia G, Gesi M, et al. Time-course and dose-response study on the effects of chronic L-dopa administration on striatal dopamine levels and dopamine transporter following MPTP toxicity. Brain Res 2000;887:110-117.
161. Mytilineou C, Walker RH, Jnobaptiste R, Olanow CW. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther 2003;304:792-800.
162. Hefti F, Melamed E, Bhawan J, Wurtman RJ. Long-term administration of L-dopa does not damage dopaminergic neurons in the mouse. Neurology 1981;31:1194-1195.
163. Ferrario JE, Delfino MA, Stefano AV, et al. Effects of orally administered levodopa on mesencephalic dopaminergic neurons undergoing a degenerative process. Neurosci Res 2003;47:431-436.
164. Datla KP, Blunt SB, Dexter DT. Chronic L-DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-OHDA or FeCl(3) nigrostriatal lesions. Mov Disord 2001;16:424-434.
165. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin, 6-hydroxydopamine. Mov Disord 1993;8:129-133.
166. Lyras L, Zeng BY, McKenzie G, Pearce RK, Halliwell B, Jenner P. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomolgus monkeys. J Neural Transm 2002;109:53-67.
167. Graham DG, Tiffany SM, Bell W Jr, Gutknecht WF. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978;14:644-653.
168. Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990; 26:428-435.
169. Tanaka M, Sotomatsu A, Kanai H, Hirai S. Dopa and dopamine cause cultured neuronal death in the presence of iron. J Neurol Sci 1991;101:198-203.
170. Mena MA, Pardo B, Casarejos MJ, Fahn S; Garcia de Yebenes J. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 1992;7:23-31.
171. Clement MV, Ramalingam J, Long LH, Halliwell B. The in vitro cytotoxicity of ascorbate depends on the culture medium used to perform the assay and involves hydrogen peroxide. Antioxid Redox Signal 2001;3:157-163.
172. Long LH, Halliwell B. Oxidation and generation of hydrogen peroxide by thiol compounds in commonly used cell culture media. Biochem Biophys Res Commun 2001;286:991-994.
173. Hisanaga K, Sagar SM, Sharp FR. Ascorbate neurotoxicity in cortical cell culture. Ann Neurol 1992;31:562-565.
174. Mena MA, Casarejos MJ, Carazo A, Paino CL, Garcia-de-Yebenes J. Glia conditioned medium protects fetal rat midbrain neurones in culture from L-DOPA toxicity. Neuroreport 1996;7: 441-445.
175. Mena MA, Casarejos MJ, Carazo A, Paino CL, Garcia-de-Yebenes J. Glia protect fetal midbrain dopamine neurons in culture from L-DOPA toxicity through multiple mechanisms. J Neural Transm 1997;104:317-328.
176. Han S-K, Mytilineou C, Cohen G. L-dopa up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996;66:501-510.
177. Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-DOPA in postnatal midbrain dopamine neuron/cortical astrocyte cocultures. J Neurochem 1997;69:1398-1408.
178. Clement M-V, Long LH, Ramalingam J, Halliwell B. The cytotoxicity of dopamine may be an artefact of cell culture. J Neurochem 2002;81:414-421.
179. Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci 2003;991:120-131.
180. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003;53(Suppl. 3):S26-S36.
181. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988;24:574-576.
182. Banati RB, Daniel SE, Blunt SB. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 1998;13:221-227.
183. Hirsch EC, Hunot S, Damier P, Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol 1998;44(Suppl. 1):S115-S120.
184. Orr CF, Rowe DB, Halliday GM. An inflammatory review of Parkinson's disease. Prog Neurobiol 2002;68:325-340.
185. Mizuno Y, Yoshino H, Ikebe S-I, et al. Mitochondrial dysfunction in Parkinson's disease. Ann Neurol 1998;44(Suppl. 1):S99-S109.
186. Petrozzi L, Lucetti C, Gambaccini G, et al. Cytogenetic analysis oxidative damage in lymphocytes of Parkinson's disease patients. Neurol Sci 2001;22:83-84.
187. Migliore L, Petrozzi L, Lucetti C, et al. Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology 2002;58:1809-1815.
188. Kikuchi A, Takeda A, Onodera H, et al. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis 2002;9:244-248.
189. Hsu LJ, Sagara Y, Arroyo A, et al. alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 2000;157: 401-410.
190. Junn E, Mouradian MM. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett 2002;320:146-150.
191. Lee MH, Hyun D-H, Halliwell B, Jenner A. Effect of the over-expression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem 2001;76:998-1009.
192. Hyun D-H, Lee MH, Hattori N, et al. Effect of wild-type or mutant parkin on oxidative damage, nitric oxide, antioxidant defenses, and the proteasome. J Biol Chem 2002;277:28572-28577.